U.S. Food and Drug
Administration (FDA) approved
idelalisib (Zydelig tablets, Gilead
Sciences, Inc.) for the treatment
of patients with relapsed
chronic lymphocytic leukemia, in
combination with rituximab, for
whom rituximab alone would be
considered appropriate therapy
due to other co-morbidities.
Idelalisib is not yet approved by
the TGA for marketing.
The FDA has also approved
Ruconest, the first recombinant C1-
esterase inhibitor for the treatment
of acute attacks in patients with
hereditary angioedema.
Ruconest is not yet approved for
use in Australia.The above article was sent to subscribers in Pharmacy Daily's issue from 25 Jul 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Jul 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.